October 2021 - The Column Group

Mr. Jeff Goater joins The Column Group as Venture Partner

The Column Group announces the hiring of Mr. Jeff Goater. Previously, Mr. Goater served as Chief Executive Officer of Surface Oncology. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team.

Mr. Jeff Goater joins The Column Group as Venture Partner Read More »

Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

Accent Therapeutics and Ipsen Signed an Exclusive Worldwide Collaboration, Targeting the RNA Modifying Protein, METTL3

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Mr. Jeff Goater joins The Column Group as Venture Partner